{"id":"fencibutirol","rwe":[{"pmid":"7095144","year":"1982","title":"[Microbiological hydroxylation of fencibutirol. Isolation and choleretic activity of a metabolite].","finding":"","journal":"Il Farmaco; edizione scientifica","studyType":"Clinical Study"},{"pmid":"7095143","year":"1982","title":"[Stereochemistry of fencibutirol. Preparation and choleretic activity of its geometric isomer].","finding":"","journal":"Il Farmaco; edizione scientifica","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"biligen","offLabel":[],"synonyms":["fencibutirol","verecolene","biligen"],"timeline":[],"approvals":[],"brandName":"Biligen","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and Biligen is a key that fits into those locks. When Biligen binds to its target, it helps to unlock the cell's function, allowing it to work properly and treat a specific condition. This is a simplified explanation of how Biligen works at a cellular level.","oneSentence":"Biligen works by binding to a specific target, altering its function to produce a therapeutic effect.","technicalDetail":"Biligen's mechanism of action involves binding to a specific protein target, modulating its activity through allosteric or competitive inhibition, leading to a downstream effect on cellular function."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3746","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FENCIBUTIROL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:25:26.049843","biosimilars":[],"competitors":[],"genericName":"fencibutirol","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"H2V165956A","CHEBI":"CHEBI:135081","INN_ID":"3443","UMLSCUI":"C0060160","ChEMBL_ID":"CHEMBL2104299","KEGG_DRUG":"D04141","PUBCHEM_CID":"71170","MESH_SUPPLEMENTAL_RECORD_UI":"C035344"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1982 May","pmid":"7095144","title":"[Microbiological hydroxylation of fencibutirol. Isolation and choleretic activity of a metabolite].","journal":"Il Farmaco; edizione scientifica"},{"date":"1982 May","pmid":"7095143","title":"[Stereochemistry of fencibutirol. Preparation and choleretic activity of its geometric isomer].","journal":"Il Farmaco; edizione scientifica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Biligen, also known as FENCIBUTIROL, is a small molecule modality developed by an unknown entity. Its current owner is also unknown. The target and drug class of Biligen are not specified. It is not known if Biligen is FDA approved or has any approved indications. The commercial status of Biligen, including whether it is patented or generic, is also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}